Exome Asset Management LLC Makes New Investment in Blueprint Medicines Co. (NASDAQ:BPMC)

Exome Asset Management LLC acquired a new stake in Blueprint Medicines Co. (NASDAQ:BPMC) during the 3rd quarter, Holdings Channel.com reports. The firm acquired 36,700 shares of the biotechnology company’s stock, valued at approximately $3,395,000. Blueprint Medicines makes up 2.3% of Exome Asset Management LLC’s holdings, making the stock its 15th biggest holding.

Several other institutional investors also recently bought and sold shares of the company. Triad Wealth Partners LLC acquired a new position in Blueprint Medicines during the 2nd quarter worth approximately $27,000. Quarry LP purchased a new stake in shares of Blueprint Medicines during the 3rd quarter worth $32,000. Covestor Ltd grew its stake in shares of Blueprint Medicines by 206.7% during the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 403 shares in the last quarter. CWM LLC grew its stake in shares of Blueprint Medicines by 114.6% during the second quarter. CWM LLC now owns 1,105 shares of the biotechnology company’s stock worth $119,000 after purchasing an additional 590 shares in the last quarter. Finally, Van ECK Associates Corp increased its holdings in Blueprint Medicines by 13.3% in the second quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 131 shares during the last quarter.

Blueprint Medicines Price Performance

BPMC stock opened at $93.19 on Friday. The firm has a 50 day moving average of $92.03 and a 200-day moving average of $97.52. The company has a market cap of $5.92 billion, a price-to-earnings ratio of -44.17 and a beta of 0.59. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09. Blueprint Medicines Co. has a 12-month low of $72.24 and a 12-month high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The firm had revenue of $128.20 million during the quarter, compared to analysts’ expectations of $127.56 million. During the same period in the previous year, the firm posted ($2.20) earnings per share. Blueprint Medicines’s revenue was up 126.5% on a year-over-year basis. As a group, equities analysts expect that Blueprint Medicines Co. will post -3.68 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on BPMC shares. Wells Fargo & Company dropped their price objective on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. HC Wainwright reiterated a “buy” rating and set a $135.00 price target on shares of Blueprint Medicines in a research note on Friday, November 15th. Wedbush reissued an “outperform” rating and issued a $135.00 price target on shares of Blueprint Medicines in a research report on Thursday, November 14th. Needham & Company LLC reissued a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a report on Friday, November 15th. Finally, Guggenheim reiterated a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $122.11.

Insiders Place Their Bets

In other Blueprint Medicines news, insider Fouad Namouni sold 3,633 shares of the firm’s stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total transaction of $324,499.56. Following the completion of the transaction, the insider now owns 69,070 shares of the company’s stock, valued at approximately $6,169,332.40. This trade represents a 5.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Kate Haviland sold 2,353 shares of the business’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $96.60, for a total transaction of $227,299.80. Following the completion of the transaction, the chief executive officer now directly owns 150,824 shares of the company’s stock, valued at $14,569,598.40. The trade was a 1.54 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 8,260 shares of company stock worth $768,057. Insiders own 4.21% of the company’s stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.